BioArctic’s partner Eisai launches Leqembi in South Korea to treat MCI due to AD or mild AD dementia: Stockholm, Sweden Friday, November 29, 2024, 16:00 Hrs [IST] BioArctic ABs ...

Eisai (ESAIY) and Biogen (BIIB) announced that the humanized anti-soluble aggregated amyloid-beta, or Abeta, monoclonal antibody Leqembi has ...

Cassava Sciences’ SAVA stock shed more than 80% of market value on Monday after the company reported that its lead pipeline ...

Eisai and the National Center of Neurology and Psychiatry in Tokyo will study the link between APOE genotype and safety and efficacy of Leqembi.

The 2024 MM+M Agency 100 honoree tapped Coman for the top spot in order to lead clients across the industry through a new era ...

Biogen Inc. (NASDAQ:BIIB) also benefits from its strong pipeline, which shows promise in areas like lupus and Alzheimer’s ...

Panelists in this recent #TrendTalks discussion, “Activating Omnichannel Without Omniburden, sponsored by Relevate Health,” ...

The decision in Europe follows an approval granted by the US Food and Drug Administration (FDA) in March this year.

In the wake of a market pull in obesity nearly five years ago, the other shoe has dropped for Eisai’s serotonin 2C receptor ...

Reversing an earlier decision, European regulators recommended that the Alzheimer’s therapy Leqembi should be approved ...

The European Union’s drugs regulator on Thursday (November 14, 2024) recommended approval of Eisai and Biogen’s Leqembi for some patients with early Alzheimer’s disease, reversing its ...

Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.